During the corresponding time, Stoke Therapeutics Inc saw a revenue deteriorated by -96.07 % year on year, sequentially revenue grew by 344.29 %. While revenue at the Stoke Therapeutics Inc 's corporate clients
Stoke Therapeutics, Inc., a Nasdaq-listed biotechnology innovator, continues to make significant strides in RNA medicine with its lead investigational therapy, zorevunersen, aimed at modifying diseases such as Dravet syndrome. In recent updates, the company has reported financial results for both the third quarter of 2025 and the full year of 2024, alongside strategic participation in investor conferences, reflecting its progress in the biotech arena. Financial Health and Business Updates Stoke Therapeutics financial reports for the third quarter of 2025 reveal pertinent insights into the company s fiscal health and operational strategy. Despite the ebbs and flows characteristic of the biotech sector, Stoke...
Stoke Therapeutics, Inc. (Nasdaq: STOK), based in Bedford, Massachusetts, is making noteworthy strides in the biotechnology sector with its pioneering approach to RNA medicine. Focused on restoring protein expression, Stoke Therapeutics is positioning itself as a leader in innovative therapeutics aimed at addressing genetic disorders. Recent announcements regarding upcoming investor conferences, groundbreaking clinical data, and robust financial updates collectively emphasize the company’s commitment and potential for growth in a highly specialized field. Upcoming Investor EngagementsStoke Therapeutics has announced that it will be presenting at two significant investor conferences in March 2025. The first...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on addressing severe diseases through RNA-based therapies, is set to present promising clinical data on its leading candidate, zorevunersen (STK-001), at the 15th European Epilepsy Congress (EEC) in Rome, Italy, from September 7 to 11, 2024. This presentation aims to highlight zorevunersen s potential as the first disease-modifying treatment for Dravet syndrome, a rare and severe form of epilepsy that often leads to frequent seizures, developmental delays, and increased mortality risk in affected children.Zorevunersen is an innovative antisense oligonucleotide (ASO) designed to target the underlying genetic causes of Dravet syndrome by ...
BEDFORD, Mass. - Stoke Therapeutics, a prominent biotechnology company engaged in developing RNA-based medicines to tackle severe diseases, has recently announced that its management will be presenting at two major investor conferences. The company s participation underscores its ongoing commitment to addressing the root causes of debilitating illnesses by upregulating protein expression.Firstly, Stoke Therapeutics is set to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 4:00 p.m. ET. This conference marks a significant platform for the company to share updates on its groundbreaking RNA-based treatments, which have shown considerable potential in tackling s...
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerBedford, MA Stoke Therapeutics, Inc. (Nasdaq: STOK), a prominent biotechnology company focusing on developing RNA-based medicines to tackle the root cause of severe diseases, announced the recent hiring of Thomas Leggett as its new Chief Financial Officer. The appointment comes as the company strives to strengthen its financial strategy and operations.As the Chief Financial Officer, Mr. Leggett will take charge of overseeing all financial aspects of the company. His extensive experience and expertise in finance will play a crucial role in driving Stoke Therapeutics towards its goals to revolutionize disease treatment using RNA-based thera...
Sources:
Stoke Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Stoke Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Stoke Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
64.75 %